Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Optimal Use of Venetoclax in AML

July 20th 2020

VIALE Studies in AML

July 20th 2020

Utilization of Second-Generation FLT3 Inhibitors in AML

July 20th 2020

Second-Generation FLT3 Inhibitors in AML

July 20th 2020

FLT3-Mutated AML: Midostaurin and Chemotherapy

July 20th 2020

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

July 20th 2020

FLT3 Genetic Alterations in AML

July 20th 2020

Dr. Davids on the Design of the Phase 3 UNITY Trials in Relapsed/Refractory CLL and MCL

July 17th 2020

Matthew S. Davids, MD, MMSc, discusses the design of the UNITY trials in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Shaughnessy on Available CAR T-Cell Therapies in R/R Hematologic Malignancies

July 17th 2020

Paul J. Shaughnessy, MD, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

Ongoing Trial Evaluates Zanubrutinib in BTK-Intolerant B-Cell Malignancies

July 17th 2020

Ian W. Flinn, MD, PhD, discusses the adverse effects associated with BTK inhibitors in B-cell malignancies, as well as the design of an ongoing phase 2 study with zanubrutinib.

Expert Confirms Efficacy, Safety in Final ASCEND Data With Acalabrutinib in Relapsed/Refractory CLL

July 17th 2020

Paolo Ghia, MD, PhD, discusses the final results from the phase 3 ASCEND trial with acalabrutinib monotherapy in patients with relapsed/refractory CLL.

Liso-Cel Takes Step Toward EU Approval in B-Cell Lymphomas

July 17th 2020

The European Medicines Agency has validated a Marketing Authorization Application for the CD19-directed CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and grade 3B follicular lymphoma following at least 2 prior therapies.

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Novel Therapies: R2-GDP-GOTEL and Smart Start

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Novel Treatment Combinations for R/R DLBCL

July 17th 2020